http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108558867-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_966a6c1f382ec9bcb5e3839dfd73e5b8
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-444
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-437
filingDate 2014-08-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bffdb4a08f26f48893bdd712b2b00c55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_671bd2b5899f3f81654a735b597a76ad
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_99d2e0e345a691f013248904945d6be1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_59ac2a1a94018d8b29f0514f32a773e4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4c2381039933d47cd4a805d472b0c268
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_360feb2487de424957c4e63e4ec59719
publicationDate 2018-09-21-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CN-108558867-A
titleOfInvention Pyrrolopyridine or pyrazolopyridine derivatives
abstract The present invention relates to pyrrolopyridine or pyrazolopyridine derivatives. In particular, the present invention relates to compounds of formula I, or to pharmaceutically acceptable acid addition salts, racemic mixtures thereof or corresponding enantiomers and/or optical isomers thereof. The compounds of the present invention are positive allosteric modulators (PAMs) of muscarinic M1 receptors and are therefore useful in the treatment of diseases mediated by muscarinic M1 receptors, such as Alzheimer's disease, cognitive impairment, psychiatric Schizophrenia, pain, or sleep disturbance.
priorityDate 2013-08-30-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2011041143-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2009325970-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2013106795-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2010019391-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID466131716
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID466522491

Total number of triples: 36.